Literature DB >> 10469361

Pentoxifylline attenuates experimental mesangial proliferative glomerulonephritis.

Y M Chen1, C T Chien, M I Hu-Tsai, K D Wu, C C Tsai, M S Wu, T J Tsai.   

Abstract

BACKGROUND: Accumulation of glomerular macrophages, proliferation of mesangial cells (MCs), and deposition of extracellular matrix proteins are pathobiological hallmarks of glomerulonephritis. We previously reported that a clinically available nonselective inhibitor of cyclic 3',5'-nucleotide phosphodiesterase, pentoxifylline (PTX), inhibits proliferation of cultured rat MCs, as well as collagen production by these cells. In this study, we investigated the in vivo effects of PTX on rat anti-Thy1 disease, a model of mesangial proliferative nephritis.
METHODS: Anti-Thy1 nephritis was induced in Sprague-Dawley rats by injecting mouse anti-rat Thy1 antibodies intravenously. Nephritic rats were randomly assigned to receive PTX (0.1 g/kg/day) or vehicle (phosphate-buffered saline) and were sacrificed at various time points. Paraffin kidney sections were stained with hematoxylin and periodic acid-Schiff reagents for glomerular histology. Frozen kidney sections were stained by monoclonal antibodies against proliferating cell nuclear antigen, ED-1, and alpha-smooth muscle actin and were visualized by color development from a horseradish peroxidase reaction. Monocyte chemoattractant protein-1 (MCP-1), intercellular adhesion molecule-1 (ICAM-1), and various extracellular matrix mRNAs were analyzed by Northern blotting. Urine protein concentrations were determined by Lowry's method.
RESULTS: Nephritic rats treated with PTX excreted less urinary protein on day 5 of nephritis than vehicle-treated nephritic rats. In periodic acid-Schiff-stained kidneys from PTX-treated nephritic rats, there was attenuation of both glomerular cellularity and glomerular sclerosis compared with vehicle-treated nephritic rats. PTX decreased the augmented glomerular mRNA levels of MCP-1 and ICAM-1 at two hours and on day 1 of nephritis. Immunoreactive staining showed that PTX reduced the number of proliferating glomerular macrophages on days 1, 2, and 3, but not at two hours of nephritis, compared with vehicle-treated nephritic rats. On day 5, PTX decreased the number of activated proliferating MCs and attenuated the glomerular mRNA levels of type I (alpha1), type III (alpha1), and type IV (alpha1) collagen and fibronectin compared with vehicle-treated nephritic rats.
CONCLUSION: The administration of PTX to rats with anti-Thy1 disease reduces accumulation and proliferation of glomerular macrophages, attenuates proteinuria, suppresses activation and proliferation of MCs, and ameliorates glomerular sclerosis. These results suggest that PTX may have a suppressive effect in acute phases or relapses of mesangial proliferative glomerulonephritis.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10469361     DOI: 10.1046/j.1523-1755.1999.00636.x

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  16 in total

1.  Pentoxifylline Attenuates Proteinuria in Anti-Thy1 Glomerulonephritis via Downregulation of Nuclear Factor-κB and Smad2/3 Signaling.

Authors:  Yung-Ming Chen; Wen-Chih Chiang; Yalin Yang; Chun-Fu Lai; Kwan-Dun Wu; Shuei-Liong Lin
Journal:  Mol Med       Date:  2015-04-13       Impact factor: 6.354

Review 2.  Inflammation and diabetic nephropathy.

Authors:  Carmen Mora; Juan F Navarro
Journal:  Curr Diab Rep       Date:  2006-12       Impact factor: 4.810

3.  Therapeutics in renal disease: the road ahead for antiproliferative targets.

Authors:  Peter J Nelson; Stuart J Shankland
Journal:  Nephron Exp Nephrol       Date:  2005-12-07

Review 4.  Effect of pentoxifylline in proteinuric chronic kidney disease: a systematic review and meta-analysis.

Authors:  Xiangpin Jiang; Shengguo Zhou; Jing Yao; Xianglei Kong; Meiyu Cui
Journal:  J Nephrol       Date:  2015-10-28       Impact factor: 3.902

5.  Inhibition of tubulointerstitial fibrosis by pentoxifylline is associated with improvement of vascular endothelial growth factor expression.

Authors:  Qiu-gen Zhou; Fa-lei Zheng; Fan-fan Hou
Journal:  Acta Pharmacol Sin       Date:  2008-12-15       Impact factor: 6.150

6.  Effects of pentoxifylline in adriamycin-induced renal disease in rats.

Authors:  Yusuf Usta; Ugur Burcin Ismailoglu; Aysin Bakkaloglu; Dicle Orhan; Nesrin Besbas; Inci Sahin-Erdemli; Seza Ozen
Journal:  Pediatr Nephrol       Date:  2004-06-16       Impact factor: 3.714

7.  Effect of add-on pentoxifylline on proteinuria in membranous glomerulonephritis: a 6-month placebo-controlled trial.

Authors:  Shirinsadat Badri; Simin Dashti-Khavidaki; Farrokhlegha Ahmadi; Mitra Mahdavi-Mazdeh; Mohammad-Reza Abbasi; Hossein Khalili
Journal:  Clin Drug Investig       Date:  2013-03       Impact factor: 2.859

Review 8.  A review of the potential protective effects of pentoxifylline against drug-induced nephrotoxicity.

Authors:  Zahra Nasiri-Toosi; Simin Dashti-Khavidaki; Hossein Khalili; Mahboob Lessan-Pezeshki
Journal:  Eur J Clin Pharmacol       Date:  2012-11-22       Impact factor: 2.953

9.  Stereological comparison of the effects of pentoxifylline, captopril, simvastatin, and tamoxifen on kidney and bladder structure after partial urethral obstruction in rats.

Authors:  Mehdi Shirazi; Mohammad-Reza Soltani; Zahra Jahanabadi; Mohammad-Amin Abdollahifar; Nader Tanideh; Ali Noorafshan
Journal:  Korean J Urol       Date:  2014-11-10

Review 10.  Cyclic nucleotide signalling in kidney fibrosis.

Authors:  Elisabeth Schinner; Veronika Wetzl; Jens Schlossmann
Journal:  Int J Mol Sci       Date:  2015-01-22       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.